Get the Stockscreener App
2.88
25.76%
0.59
After Hours:
2.62
-0.26
-9.03%
Gri Bio Inc stock is traded at $2.88, with a volume of 7.39M.
It is up +25.76% in the last 24 hours and up +81.13% over the past month.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
See More
Previous Close:
$2.29
Open:
$2.34
24h Volume:
7.39M
Relative Volume:
23.59
Market Cap:
$6.30M
Revenue:
-
Net Income/Loss:
$-10.91M
P/E Ratio:
-0.0362
EPS:
-79.5513
Net Cash Flow:
$-12.14M
1W Performance:
+50.00%
1M Performance:
+81.13%
6M Performance:
+20.00%
1Y Performance:
-93.14%
1-Day Range:
$2.33
$3.36
1-Week Range:
$1.84
$3.36
52-Week Range:
$1.36
$80.36
Gri Bio Inc Stock (GRI) Company Profile
Name
Gri Bio Inc
Sector
Industry
Phone
(619) 400-1171
Address
2223 AVENIDA DE LA PLAYA, LA JOLLA
Compare GRI vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GRI
Gri Bio Inc
|
2.88 | 3.65M | 0 | -10.91M | -12.14M | -79.55 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Gri Bio Inc Stock (GRI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-24 | Initiated | H.C. Wainwright | Buy |
Gri Bio Inc Stock (GRI) Latest News
What Put GRI Bio (NASDAQ:GRI) on the Nasdaq Composite Radar? - Kalkine Media
GRI Bio Surges As Phase 2a IPF Drug Data Nears - StocksToTrade
GRI Bio Jumps As Positive IPF Drug Data Nears ERS Stage - timothysykes.com
GRI-0621 Improves FVC, Reduces Fibrotic Biomarkers in IPF - hcplive.com
GRI Bio Surges As Phase 2a IPF Data Near ERS Reveal - timothysykes.com
GRI Bio Company Profile & Introduction - Moomoo
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
GRI|GRI Bio Inc|Price:2.880|Chg%:+0.590 - TradingKey
GRI Bio will present data on its once-daily oral drug in Barcelona this September - Stock Titan
GRI Bio Featured in "Why Now" On-Demand Video Webcast - Yahoo Finance
OSRH Stock Price and Chart — OTC:OSRH - TradingView
GRI Bio Price Target Cut to $27.00/Share From $32.00 by Ascendiant Capital - Moomoo
GRI Bio to present Phase 2a IPF drug data at ERS Congress - Investing.com Canada
GRI Bio Inc. (GRI) Climbs 3.6% to $1.73 as Buyers Defend Key SupportWyckoff Accumulation - vinanet.vn
GRI Bio Inc. Q1 2026 Earnings: Wider-than-Expected Loss of $1.61 Per Share, Yet Stock Closes Up 3.59 - vinanet.vn
GRI Q1 2026 Earnings: EPS Falls Sharply Short of Estimates as Shares Slide 5.65%Earnings Forecast Report - vinanet.vn
GRI Bio Inc reports results for the quarter ended June 30Earnings Summary - TradingView
GRI Bio, Inc. 2Q 2026: Net income $(1.64)M, EPS $(0.91) — 10-Q Summary - TradingView
Form 10-Q GRI Bio, Inc. For: Jun 30 - StreetInsider
GRI Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
GRI Bio (GRI) investors disclose 4.99% stake capped by warrant blockers - Stock Titan
GRI Q2'26 Earnings: revenue estimate is 0 USD - TradingView
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
GRI Bio Inc expected to post a loss of $1.19 a shareEarnings Preview - TradingView
GRI Bio (GRI) Jumps 15.65% to $1.70 — Breakout Above $1.78 Could Extend RallyHigh Low Breadth - dars.gov.et
GRI Bio Inc (GRI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
GRI Bio Inc. (NASDAQ: GRI) Share Price, GRI Stock News, GRI Share Price & Updates - kalkine.ca
GRI Q1 2026 Earnings: Wider-than-Expected Loss Highlights Clinical-Stage BurnBuyback Announcement Report - vinanet.vn
GRI Bio Inc (GRI) Cash Flow - TradingKey
GRI Bio Inc (GRI) Valuation: PE, PB & Fair Value Analysis - TradingKey
GRI Bio Inc (GRI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
GRI Bio Inc (GRI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
GRI|GRI Bio Inc|Price:1.420|Chg%:-0.030 - TradingKey
GRI Bio Inc (GRI) Risk Assessment: Volatility, Financial Risk & Investment Risk - tradingkey.com
GRI Bio Inc (GRI) Income Statement - TradingKey
Gri Bio, Inc. (GRI) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
TradingKey - TradingKey
GRI Bio Inc (GRI) Institutional Confidence - TradingKey
GRI Bio, Inc. Revenue Breakdown – NASDAQ:GRI - TradingView
GRI Bio Inc (GRI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Price to sales forward of GRI Bio, Inc. – NASDAQ:GRI - TradingView
CHGA Stock Price and Chart — NASDAQ:CHGA - TradingView
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
GRI Q1 2026 Earnings: EPS Misses Estimates by a Wide Margin as Pre‑Revenue Biotech Faces Increased CostsReturn On Capital - Vinanet
GRI Bio Inc. (GRI) Retreats 3.23% as Shares Test Support Near $1.42Price Surge Stocks - dars.gov.et
GRI Q1 2026 Earnings: Wider-than-Expected Loss on No RevenueEarnings Analysis - vinanet.vn
GRI Q1 2026 Earnings: EPS Misses Estimates by 76%, No Revenue ReportedReturn On Capital - vinanet.vn
GRI Bio Inc. (GRI) Q1 2026 Earnings: Significant EPS Miss Amid Pre-Revenue StageMargin Guidance - dars.gov.et
GRI Bio Inc. Q1 2026 Earnings: EPS Misses Estimates by 76%, Stock Rises 2.6% Amid Strategic Progress - Bölüm Sonu Canavarı
GRI Bio Inc. (GRI) Q1 2026 Earnings: Wider-than-Expected Loss Exceeds Estimates on Pre-Revenue StatusTech Earnings Analysis - dars.gov.et
Price to earnings forward of GRI Bio, Inc. – NASDAQ:GRI - TradingView
Gri Bio Inc Stock (GRI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):